Topic: GI ASCO Orlando 2010
I have escaped the rain and storm in California and am enjoying the rain and storm in Florida although; here it is tropical and appears periodically, only.
The GI ASCO consists of a consortium of the American Gastroenterological Institute, (AGA) the American Society of Clinical Oncology, (ASCO) the American Society for Radiation Oncology, (ASTRO) and the Society of Surgical Oncology. This three-day multidisciplinary symposium focuses on gastrointestinal cancers only.
As most of you know already the Gem/Cis combination has been established as the very first standard of treatment for Cholangiocacinoma as it has clearly demonstrated increased life expectancy. This does not mean though, that all other medications are not also still used. Various reasons may exclude certain patients, such as intolerance, inefficiency, and etc. from the Gem/Cis combination.
This board has ongoing discussions regarding adjunctive therapies for resectable cholangiocarcinoma and I thought this abstract might be of interest to you. Do remember though, this is a small study group and it is a retrospective study.
This study was conducted at Princess Margaret Hospital, Toronto, Canada; University of Toronto, Canada. Investigators: A.M Horgan, H.H. Al Husainy, S. Cleary, L.A. Dawson, C. Ma, J.J. Knox.
Background: There is no consensus on optimal adjunctive treatment strategies for respectable Bile Duct Cancer. Current approaches involve (neo)adjuvant chemotherapy, chemo radiation therapy or radiotherapy without supporting evidence. The aim of this study is to review treatments utilized in our institutions and explore outcomes in relation to each.
Methods: We reviewed all records of BDC patients treated at PMH between 1990 and 2007. We identified those treated with curative resection and (neo)adjuvant therapy. Age, performance status, tumor characteristics (histology, tumor location, margins and lymph node status) and treatment details (surgical procedure, CT, RT and toxicity data) were collected. A comparison of survival outcomes between RT, CRT and CT arms was undertaken and the difference
Between proportions calculated by the Chi-square test.
Results: Thirty-eight patients treated with curative resection and (neo) adjuvant therapy with a median age of 56 years (32